Vimarsana
Biggest News Aggregation in the World

Bertram Pitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bertram Pitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bertram Pitt Today - Breaking & Trending Today

Review of the European Society of Cardiology (ESC) Congress 2023 - Vimarsana News

Review of the European Society of Cardiology (ESC) Congress 2023

The European Society of Cardiology (ESC) inaugural session unfolded against the backdrop of Amsterdam, the Netherlands...

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023 - Vimarsana News

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

THE WOODLANDS, Texas, Aug. 21, 2023 -- Lexicon Pharmaceuticals, Inc. today announced that analyses of clinical study results relating to INPEFA™ , its recently approved drug for heart...

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing ... - Vimarsana News

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing ...

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug

Post-hoc Findings From Inpefa Trial Show Benefit of Starting Drug Before Discharge - Vimarsana News

Post-hoc Findings From Inpefa Trial Show Benefit of Starting Drug Before Discharge

Results show that the new heart failure drug reduces the hospitalizations and risk of death from cardiovascular events.

Sotagliflozin Can Reduce Risk of Death, Readmission at 90 Days in People with Heart Failure - Vimarsana News

Sotagliflozin Can Reduce Risk of Death, Readmission at 90 Days in People with Heart Failure

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.